CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 26 enrolled
Drug / intervention
zilucoplan (RA101495)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05514873
NCT05514873Phase 3Completed
CompareCT.gov

A Phase 3b, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Zilucoplan in Participants With Generalized Myasthenia Gravis Switching From Intravenous Complement Component 5 Inhibitors to Subcutaneous Zilucoplan

UCB Biopharma SRL·interventional·Posted Aug 25, 2022·Updated Sep 3, 2025

In Brief

A Phase 3 clinical trial evaluating zilucoplan (RA101495) for Generalized Myasthenia Gravis. Completed, enrolled 26 participants across 12 sites.

Detailed Summary

The purpose of the study is to evaluate the safety and tolerability of switching from intravenous (IV) complement component 5 (C5) inhibitors to subcutaneous (SC) Zilucoplan in study participants with generalized myasthenia gravis (gMG)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGeneralized Myasthenia Gravis
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2023202420252026
First PostedAug 25, 2022
Enrollment StartOct 31, 2022
Primary CompletionMar 13, 2024
Study CompletionOct 23, 2024
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 3.9 years ago

Interventions

zilucoplan (RA101495)drug

Subcutaneous injection